Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$2.04 USD
+0.11 (5.70%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Coherus BioSciences (CHRS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.33 | $11.00 | $4.00 | 331.61% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Coherus BioSciences comes to $8.33. The forecasts range from a low of $4.00 to a high of $11.00. The average price target represents an increase of 331.61% from the last closing price of $1.93.
Analyst Price Targets (6 )
Broker Rating
Coherus BioSciences currently has an average brokerage recommendation (ABR) of 1.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.60 a month ago based on 10 recommendations.
Of the 10 recommendations deriving the current ABR, seven are Strong Buy, representing 70% of all recommendations. A month ago, Strong Buy represented 70%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.60 | 1.60 | 1.60 | 1.60 | 1.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/14/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
1/23/2024 | Robert W. Baird & Co. | Colleen M Kusy | Strong Buy | Strong Buy |
1/23/2024 | Truist Securities | Robyn Karnauskas | Strong Buy | Strong Buy |
11/8/2023 | Maxim Group | Michael Okunewitch | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.60 |
ABR (Last week) | 1.60 |
# of Recs in ABR | 10 |
Average Target Price | $8.33 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -0.05 |